←SLSSELLAS Life Sciences GroupOur view: NeutralFull analysisעברית
Updated 17 Nov 2026
The company · 1 · Who is this company?

SELLAS is testing a drug to keep leukemia from coming back

GPS

an injection that trains the immune system

SLS009

a second drug, for patients other drugs fail

13 staff

others run its trials and make its drugs

A small New York company with no product on sale. It develops two drugs for acute myeloid leukemia, a fast-moving blood cancer, and pays partners to test and make them.

The company · 2 · What exactly does it sell?

It sells nothing yet; both drugs are still in trials

$0sales so far
$3.1Minterest earned on its cash in nine months

Until a drug is approved, its only income is interest on cash raised from selling shares. Every dollar it spends goes on trials and staff.

The company · 3 · How does it make money?

Selling shares pays for the trials

$134.7Mcash in September 2026
$22.4Mcash used in nine months
$85.1Mpaid in by warrant holders in 2026

If GPS is approved, SELLAS would sell it in the US and Europe and pay a royalty of a few percent to Memorial Sloan Kettering, where it was invented.

Is it a good business? · 4 · What gives it an edge?

Nothing is approved for its patients, if its trial works

Onuregthe one approved drug, for a first remission only
12 yearsUS protection from copies for an approved biologic

If GPS shows patients live longer, it would be the first drug approved to keep the disease away after a second round of treatment, protected for years by the rules.

Is it a good business? · 5 · What is the catch?

The proof so far is ten patients

10patients in the earlier GPS study
AbbVieits drugs are often kept going after remission
2026year some GPS patents run out

Listed rivals: ABBV · BMY · SNDX

The earlier study compared GPS patients with others who were not picked at random, so healthier patients may simply have done better.

Is it a good business? · 6 · What does its record show?

The trial finished counting, ten months later than registered

Trial127patients in the final trial
Count80deaths that trigger the final count, reached in October 2026
Shares203.9Mshares, from 74.0M at the end of 2024

The trial registry had expected the final count by December 2025. Meanwhile the company funded itself by issuing shares and lost an arbitration against its Chinese partner.

Is it a good business? · 7 · How much room is there to grow?

About 8,750 patients a year could use it, by its own count

22,720new US cases of this leukemia expected in 2026
8,750patients in a second remission, US, Europe and Japan
$129,238what Medicare paid per patient for Onureg in 2024

The 8,750 is the company's arithmetic from older reports. At Onureg's price it would be about $1.1B a year before any share of the market.

Is it a good business? · 8 · Who is in charge?

The founder has run it since 2012

Since 2012Angelos Stergiou, founder and chief executive
1.3%of shares owned by officers and directors
$676,000chief executive's salary in 2025

His bonus is tied to clinical and funding goals. Insiders own little of the company, and one director bought shares in 2025.

The story right now · 9 · Why does keeping a remission matter?

Most patients relapse, and relapse after a second remission usually kills

33.4%of patients alive five years after diagnosis
11,500US deaths expected in 2026

Treatment can clear the visible cancer, a remission, but a few hidden cells often survive and regrow it. A drug that stops that regrowth is what GPS is trying to be.

The story right now · 10 · Why does one result matter so much?

One trial result decides most of what the company is worth

  1. Patients split in twoGPS or the usual care, at random.
  2. Count the deathsThe result is read at 80.
  3. Compare survivalLonger life on GPS, unlikely by chance?
  4. Yes or noA miss leaves mostly cash.

A drug can only be sold once regulators approve it, and they look for a fair comparison. Before the result nobody outside the trial's independent committee knows which way it went.

The story right now · 11 · What changed lately?

The final count is in, and the result is due this month

28 Octthe 80th death, which triggers the final count
-53%the shares from their June high
28.3%of tradable shares sold short

Mixed quarter

The company promised the trial result in November 2026 and the first SLS009 data in new patients by the end of the year.

The story right now · 12 · What is everyone arguing about?

Will patients on GPS live longer?

Many investors think

It will probably work, and the slow pace of deaths shows it

We think

It may work, but the proof is thin and success is already in the price

The deaths are counted across both groups together, so their pace cannot say which group is doing better.

The price and our view · 13 · What is a share worth?

No single value here: the price already pays for success

0.6×if it works
5%kept if it fails

Multiples of the company's value when the bet was last struck, 16 Nov 2026.

We put no single value on a share, because there are no sales. The price pays about $1.39B more than the cash, roughly nine years of what an approved GPS might sell.

The price and our view · 14 · How could we be wrong?

One result, thin proof and more shares to come

One resultBiggest

A miss leaves mostly cash.

Thin proofShowing now

Ten patients in the earlier study.

Open trialWatch

Everyone knew who got GPS.

More sharesUnknown

A launch costs more than the cash.

Even a success may need new shares to pay for a sales force, which would shrink each holder's slice.

The price and our view · 15 · How will we know?

The trial result decides it, this month

Patients on GPS clearly live longer, with mild side effectsWe turn positive
Strong SLS009 data in newly diagnosed patientsGood sign
The trial misses its survival goalWe turn negative
NOV 2026-

The REGAL trial result, promised for November 2026. A drug developer's big tests are its trial results; this is the one that matters.

Our view moves on these trial events and on the price falling to about five times what the company owns, since we put no single value on a share here.

The price and our view · 16 · So, what do we think?

A coin flip whose winning side is already in the price

Priced for successthe kind of bet this is

NeutralLow conviction

SELLAS may have a first-of-its-kind leukemia drug, but the proof is thin and the price already pays for success, while a failure leaves about a twentieth in cash. Neutral.

↑ ↓ to move · C for contents